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Abstract
Genetic association studies, in particular the genome-wide association study (GWAS) design, have pro-
vided a wealth of novel insights into the aetiology of a wide range of human diseases and traits, in
particular cardiovascular diseases and lipid biomarkers. The next challenge consists of understanding the
molecular basis of these associations. The integration of multiple association datasets, including gene
expression datasets, can contribute to this goal. We have developed a novel statistical methodology to
assess whether two association signals are consistent with a shared causal variant. An application is
the integration of disease scans with expression quantitative trait locus (eQTL) studies, but any pair
of GWAS datasets can be integrated in this framework. We demonstrate the value of the approach by
re-analysing a gene expression dataset in 966 liver samples with a published meta-analysis of lipid traits
including > 100, 000 individuals of European ancestry [1]. Combining all lipid biomarkers, our re-analysis
supported 29 out of 38 reported colocalisation results with eQTLs and identified 14 new colocalisation
results, hence highlighting the value of a formal statistical test. In two cases of reported eQTL-lipid pairs
(IFT172, TBKBP1) for which our analysis suggests that the eQTL pattern is not consistent with the
lipid association, we identify alternative colocalisation results with GCKR and KPNB1, indicating that
these genes are more likely to be the causal in these genomic intervals. A key feature of the method is
the ability to derive the output statistics from single SNP summary statistics, hence making it possible
to perform systematic meta-analysis type comparisons across multiple GWAS datasets (implemented on-
line at http://coloc.cs.ucl.ac.uk/coloc/). Our methodology provides information about candidate causal
genes in associated intervals and has direct implications for the understanding of complex diseases as well
as the design of drugs to target disease pathways.
Author Summary
Genome-wide association studies (GWAS) have found a large number of genetic regions (“loci”) affecting
clinical end-points and phenotypes, many outside coding intervals. One approach to understanding the
biological basis of these associations has been to explore whether GWAS signals from intermediate cellular
phenotypes, in particular gene expression, are located in the same loci (“colocalise”) and are potentially
mediating the disease signals. However it is not clear how to assess whether the same variants are
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2responsible for the two GWAS signals or whether it is distinct causal variants close to each other. In
this paper, we describe a statistical method which can use simply single variant summary statistics to
test for colocalisation of GWAS signals. We describe one application of our method to a meta-analysis
of blood lipids and liver expression, although any two datasets resulting from association studies can
be used. Our method is able to detect the subset of GWAS signals explained by regulatory effects and
identify candidate genes affected by the same GWAS variants. As summary GWAS data are increasingly
available, applications of colocalisation methods to integrate the findings will be essential for functional
follow-up, and will also be particularly useful to identify tissue specific signals in eQTL datasets.
Introduction
In the last decade, hundreds of genomic loci affecting complex diseases and disease relevant intermediate
phenotypes have been found and robustly replicated using genome-wide association studies (GWAS, [2]).
At the same time, gene expression measurements derived from microarray [3] or RNA sequencing [4]
studies have been used extensively as an outcome trait for the GWAS design. Such studies are usually
referred to as expression quantitative trait locus (eQTL) analysis. While GWAS datasets have provided
a steady flow of positive and replicable results, the interpretation of these findings, and in particular the
identification of underlying molecular mechanisms, has proven to be challenging. Integrating molecular
level data and other disease relevant intermediate phenotypes with GWAS results is the natural step
forward in order to understand the biological relevance of these results.
In this context, a natural question to ask is whether two independent association signals at the same
locus, typically generated by two GWAS studies, are consistent with a shared causal variant. If the
answer is positive, we refer to this situation as colocalised traits, and the likelihood that both traits
share a causal mechanism is greatly increased. A typical example involves an eQTL study and a disease
association result, which points to the causal gene and the tissue in which the effect is mediated [5–7].
The same questions can also be considered between pairs of eQTLs [8, 9], or pairs of diseases [10].
However, identifying the traits that share a common association signal is not a trivial statistical task.
Visual comparison of overlaps of association signals with an expression dataset is a step in this direction
(using for example Sanger tool Genevar http://www.sanger.ac.uk/resources/software/genevar/), but the
abundance of eQTLs in the human genome and across different tissues makes an accidental overlap
between these signals very likely [3]. Therefore visual comparison is not enough to make inferences about
causality and formal statistical tests must be used to address this question.
Nica et al. [5] proposed a methodology to rank the SNPs with an influence on two traits based on the
residual association conditional on the most associated SNP. By comparing the GWAS SNP score with
all other SNPs in the associated region, this method accounts for the local LD structure. However this is
not a formal test of a null hypothesis for, or against, colocalisation at the locus of interest. A formal test
of colocalisation has been developed in a regression framework. This is based on testing a null hypothesis
of proportionality of regression coefficients for two traits across any set of SNPs, an assumption which
should hold whenever they share causal variant(s) [11, 12]. No assumption is made about the number of
causal variants, although the method does assume that in the case of multiple causal variants, all are
shared. However, both Nica’s ranking method and proportionality testing share the drawback of having
to specify a subset of SNPs to base the test on, and Wallace [13] shows that this step can generate
significant biases. The main sources of bias are overestimation of effect sizes at selected SNPs (termed
“Winner’s curse”), and the fact that, owing to random fluctuations, the causal variant may not always
be the most strongly associated one. These factors lead to rejection of colocalisation in situations where
the causal SNP is in fact shared. Although this can be overcome in the case of proportionality testing by
averaging over the uncertainty associated with the best SNP models [13], perhaps the greatest limitation
is the requirement for individual level genotype data, which are rarely available for large scale eQTL
datasets.
3The success of GWAS meta-analyses has shown that there is considerable benefit in being able to
derive association tests on the basis of summary statistics. With these advantages in mind, He et al. [7]
developed a statistical test to match the pattern of gene expression with a GWAS dataset. This approach,
coded in the software Sherlock, can accommodate p-values as input. However, their hypothesis of interest
differs from the question of colocalisation, with the focus of the method being on genomewide convergence
of signals, assuming an abundance of trans eQTLs. In particular, SNPs that are not associated with gene
expression do not contribute to the test statistic. Such variants can provide strong evidence against
colocalisation if they are strongly associated with the GWAS outcome.
These limitations motivate the development of novel methodologies to test for colocalisation between
pairs of traits. Here, we derive a novel Bayesian statistical test for colocalisation that addresses many
of the shortcomings of existing tools. Our analysis focuses on a single genomic region at a time, with a
major focus on interpreting the pattern of LD at that locus.
Our underlying model is closely related to the approach developed by Flutre et al. [9], which considers
the different but related problem of maximising the power to discover eQTLs in expression datasets of
multiple tissues. A key feature of our approach is that it only requires single SNP p-values and their
minor allele frequencies (MAFs), or estimated allelic effect and standard error, combined with closed form
analytical results that enable quick comparisons, even at the genome-wide scale. Our Bayesian procedure
provides intuitive posterior probabilities that can be easily interpreted. A main application of our method
is the systematic comparison between a new GWAS dataset and a large catalogue of association studies
in order to identify novel shared mechanisms. We demonstrate the value of the method by re-analysing
a large scale meta-analysis of blood lipids [1] in combination with a gene expression study in 966 liver
samples [14].
Results
Overview of the method
We consider a situation where two traits (denoted by Y1, Y2) have been measured in two distinct datasets
of unrelated individuals. We assume that samples are drawn from the same ethnic group, i.e. allele
frequencies and pattern of linkage disequilibrium (LD) are identical in both populations. We consider,
for each variant, a linear trend model between the outcome phenotype Y and the genotypes X (or a
log-odds generalised linear model if one of the two outcome phenotypes Y is binary):
Y = µ+ βX + 
We are interested in a situation where single variant association p-values and MAFs, or estimated regres-
sion coefficients βˆ and their estimated precisions var(βˆ), are available for both datasets at Q variants,
typically SNPs but also indels. We make two additional assumptions and discuss later in this paper how
these can be relaxed. Firstly, that the causal variant is included in the set of Q variants, either directly
typed or well imputed [15–17]. Secondly, that at most one association is present for each trait in the
genomic region of interest. We are interested in exploring whether the data support a shared causal
variant for both traits. While the method is fully applicable to case-control outcome, we consider two
quantitative traits in this initial description.
SNP causality in a region of Q variants can be summarised for each trait using a vector of length Q of
(0, 1) values, where 1 means that the variant is causally associated with the trait of interest and at most
one entry is non-zero. A schematic illustration of this framework is provided in Figure 1 in a region that
contains 8 SNPs. Each possible pair of vectors (for traits 1 and 2, which we refer to as “configuration”)
can be assigned to one of five hypothesis:
• H0: No association with either trait
4• H1: Association with trait 1, not with trait 2
• H2: Association with trait 2, not with trait 1
• H3: Association with trait 1 and trait 2, two independent SNPs
• H4: Association with trait 1 and trait 2, one shared SNP
In this framework, the colocalisation problem can be re-formulated as assessing the support for all con-
figurations (i.e. pairs of binary vectors) in hypothesis H4.
Our method is Bayesian in the sense that it integrates over all possible configurations. This process
requires the definition of prior probabilities which are defined at the SNP level (Methods). A likelihood
can be assigned to each configuration, and these likelihoods can be summed over all configurations and
combined with the prior to assess the support for each hypotheses (H)51 The result of this procedure is
five posterior probabilities (PP0, PP1, PP2, PP3 and PP4). A large posterior probability for hypothesis
3, PP3, indicates support for two independent causal SNPs associated with each trait. In contrast, if PP4
is large, the data support a single variant affecting both traits. An illustration of the method is shown in
Figure 2 for negative (Fig 2A-B, FRK gene and LDL, PP3 > 90%) and positive (Fig 2C-D, SDC1 gene
and total cholesterol, PP4 > 80%) colocalisation results.
While the method uses Approximate Bayes Factor computations (ABF, [18], and Methods), no it-
erative computation scheme (such as Markov Chain Monte Carlo) is required. Therefore, computations
are quick and do not require any specific computing infrastructure. Precisely, the computation time
behaves as Qd, where Q is the number of variants in the genomic region and d the number distinct
associations (typically d = 2, assuming two traits and at most one causal variant per trait). For all
applications considered here, the computation time is nearly instant. Importantly, the use of ABF enable
the computation of posterior probabilities from single variant association p-values and MAFs, although
the estimated single SNP regression coefficients βˆ and their variances or standard errors are preferred for
imputed data.
Sample size required for colocalisation analysis
Given the well understood requirements for large sample size for GWAS data, we used simulations to
investigate the power of our approach. We generated pairs of eQTL/biomarker datasets assuming a
shared causal variant. We varied two parameters: the sample size of the biomarker dataset and the
proportion of the biomarker variance explained by the shared genetic variant. We set the proportion of
the eQTL variance explained by the shared variant to 10% and we used the original sample size of the
liver eQTL dataset described herein [14]. Results are shown in Figure 3. We find that given a sample
size of 2,000 individuals for the biomarker dataset, the causal variant needs to explain close to 2% of
the variance of the biomarker to provide reliable evidence in favour of a colocalised signal (lower 10th
percentile for PP4 > 80%).
Consequence of limited variant density
Until recently the assumption that, for a given GWAS signal, the causal variant in that interval had
been genotyped was unrealistic. However, the application of imputation techniques [15–17] can provide
genotype information about the majority of common genetic variants. Therefore, in situations where
a common variant drives the GWAS signal, it is now plausible that, in imputed datasets, genotype
information about this variant is available. Nevertheless, limited imputation quality can invalidate this
hypothesis. This prompted us to investigate the implication of not including the causal variant in the
genotype panel.
5To address this question, we used Illumina MetaboChip data and imputed the genotyped regions
using the Minimac software ( [17] and Methods). We then selected only the subset of variants present in
the Illumina 660K genotyping array. We simulated data under the assumption of a shared causal variant,
with 4,000 individuals in the biomarker dataset. We then computed the PP4 statistic with and without
restricting the SNP set to the Illumina 660K Chip SNPs (Figure 4). We also considered two different
scenarios, with the causal SNP included/not included in the Illumina 660W panel (Figure ?? and Figure
?? for more exhaustive simulations).
Our results show that when the causal variant is directly genotyped by the low density array, the use
of imputed data is not essential (Figure 4A). However, in cases where the causal variant is not typed or
imputed in the low density panel, the variance of PP4 is much higher (Figure 4B). In this situation, the
resulting PP4 statistic tends to decrease even though considerable variability is observed. Inspection of
simulation results in Figure 5 (bottom row for tagging SNP, leftmost graph for shared causal variant)
shows that while PP4 tends to be lower than for its counterpart with complete genotype data (top row,
leftmost graph), PP3 remains low. This indicates that more probability is given to PP0, PP1 and PP2,
which can be interpreted as a loss of power rather than misleading inference in favour of distinct variants
for both traits.
Comparison with existing colocalisation tests
We compared the behaviour of our proposed test with that of proportional colocalisation testing [11,13]
in the specific case of a biomarker dataset with 10,000 samples (Figure 5). Broadly, in the case of either
a single common causal variant or two distinct causal variants, our proposed method could infer the
simulated hypotheses correctly (PP4 or PP3 > 0.9) with good confidence, and PP3 > 0.9 slightly more
often than the proportional testing p-value < 0.05. A key advantage in our Bayesian approach is the
ability to distinguish evidence for colocalisation (i.e. high PP4) from a lack of power (i.e. high PP0, PP1
or PP2). In both of these cases (high PP4 or high PP0/PP1/PP2), the use of the proportional approach
leads to failure to reject the null even though the interpretation of these situations should differ.
It has been proposed that gene expression may be subject to both global regulatory variation which
acts across multiple tissues and secondary tissue specific regulators [19]. Neither approach covers this case
explicitly in its construction, but it is instructive to examine their expected behaviour. The proportional
approach tends to reject a null of colocalisation, suggesting that a single distinct causal variant can be
sufficient to violate the null hypothesis of proportional regression coefficients. In contrast, the Bayesian
approach tends to favour the shared variant in the cases covered by our simulations (median PP4 >
median PP3), and either hypotheses H3 or H4 can potentially have strong support (PP4 > 0.9 in close to
50% of simulations, and PP3 > 0.9 in around 25% of simulations). Of course, the ultimate goal should be
to extend these tests to cover multiple causal variants, but in the meantime, it can be useful to know that
a high PP4 in our proposed Bayesian analysis indicates strong support for “at least one causal variant”
and that rejection of the null of proportionality of regression coefficients indicates that the two traits do
not share all causal variants, not that they cannot share one.
Dealing with several independent associations for the same trait
We have so far assumed that each trait is associated with at most one causal variant per locus. However,
recent studies have shown that it is not unusual to observe two or more independent associations at a
locus for a trait of interest [20]. The natural and statistically exact modification of our approach would
compute, for each trait, Bayes factors for sets of SNPs rather than single SNPs (up to n SNPs jointly to
accommodate for n distinct associations per trait). However, this approach has two drawbacks. Firstly,
the interpretation of the resulting posterior probabilities is more challenging in situations where some but
not all of the variants are shared across both traits. More importantly, the typical approach consists of
6publishing single variant summary statistics, which would prevent the use of standard summary statistics,
a key feature of our approach.
An alternative approach to account for multiple associations is motivated by the fact that, when
distinct associations for the same trait are present at a locus, the assumption of a single variant per trait
prompts the algorithm to consider only the strongest of these distinct association signals. Secondary
signals, including potential rare variant associations yielding marginal P-values, have little to no impact
on the resulting posterior probabilities. Therefore, a stepwise strategy successively conditioning on the top
SNP to reveal the secondary association signals, can be an effective approximation. In situations where
only single SNP summary statistics are available, the approximate conditional meta-analysis framework
proposed by Visscher et al [21] can be used to obtain conditional p-values. Another consequence of the
behaviour of our inference procedure when the single causal variant assumption is enforced is that the
posterior probabilities can be affected by the presence of two independent associations at the same locus
with similar levels of significance.
Application to a meta-analysis of blood lipids combined with a liver expression
dataset
Teslovich et al. [1] reported common variants associated with plasma concentrations of low-density
lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL) and triglyceride (TG) levels
in more than 100,000 individuals of European ancestry. They then reported the correlations between the
lead SNPs at the loci they found and the expression levels of transcripts in liver. For the lipid dataset
we have access only to summary statistics. The liver expression dataset used in this analyses is the same
as the one used in Teslovich et al. Teslovich et al. defined a region within 500 kilobases of the lead SNP,
and the threshold for significance is 10−8. At this threshold, they found 38 SNP-to-gene eQTLs in liver
(Supplementary Table 8 of [1]). Table S1 shows our results for these 38 previously reported colocalisa-
tions. A complete list of all our identified colocalisations (independently of previous reports) is provided
in Tables S2, S3, S4, S5 (broken down by lipid trait).
The majority of our results are consistent the findings of Teslovich et al (Table S1). However, Table
1 lists the previously reported lipid-eQTL for which we find strong support against the colocalisation
hypothesis (PP3 > 75%). To assess the role of the prior, we varied the critical parameter p12, which
codes for the prior probability that a variant is associated with both traits. Here we report the results
using the p12 = 10
−6. The complete list of results is provided in Table ??. We found six potential “false
positive” lipid-eQTL pairs for which our analysis does not support a colocalisation reported in Teslovich
et al (Table 1). In addition, we found strong evidence of distinct signals between HLA-DQ/HLA-DR and
TC (Table S1) but these results must be interpreted with caution owing to the extensive polymorphism
in the major histocompatibility complex region. Furthermore, the evidence for TMEM50A expression
and LDL (PP3 = 58%) or TC (PP3 = 60%) is not strong enough to support either models (Table S1),
so we cannot make a firm statement in this case. In one case, CEP250, our re-analysis of the expression
data did not identify an eQTL for this gene. In such a situation, both PP3 and PP4 are low and PP0,
PP1 and PP2 concentrate most of the posterior distribution.
Table 2 lists the 14 colocalised loci (15 genes) that were not reported by Teslovich et al (or in Global
Lipids Genetics Consortium [22] for the gene NYNRIN), but for which our method finds strong support for
colocalisation (PP4 > 75%). Figure S6 shows the locuszoom plots for these colocalisation results. Eleven
of these 15 genes are strong candidates for involvement in lipid metabolism and/or have been previously
suggested as candidate genes: SDC1, TGOLN2, INHBB, UBXN2B, VLDLR, VIM, CYP26A1, OGFOD1,
HP, HPR, PPARA. See supplemental for a brief overview of the function of these genes. Four others
genes have a less obvious link: CMTM6, C6orf106, CUX2, ENSG00000259359.
Three previously reported genes ( SYPL2, IFT172, TBKBP1) which, based on our re-analysis, do not
colocalise with the lipid traits, have a nearby gene with a high probability of colocalisation (resp. SORT1,
7GCKR, KPNB1). This suggests that these genes are more likely candidates in this region. To explore the
possibility that secondary signals may colocalise, we applied the stepwise regression strategy described
above to deal with several independent associations at a single locus. We performed colocalisation test
using eQTL results conditional on the top eQTL associated variant. Two of the loci (SYPL2/LDL or
TC, APOC4 and TG) showed evidence of colocalisation with expression after conditional analysis (Table
1).
An example of this stepwise procedure for the gene SYPL2 and LDL is provided in Figure 6. We find
that the top liver eQTL signal is clearly discordant with LDL association (Table 1 and Figure 6). However,
conditioning on the top eQTL signal reveals a second independent association for SYPL2 expression in
liver. This secondary SYPL2 eQTL colocalises with the LDL association (PP4 > 90%, Figure 6).
Web based resource
We developed a web site designed for integration of GWAS results using only p-values and the sample size
of the datasets (http://coloc.cs.ucl.ac.uk/coloc/). The website was developed using RWUI [23]. Results
include a list of potentially causal genes with the associated PP4 with their respective plots and ABF,
and can be viewed either interactively or returned by email.
Researchers can request a genome-wide scan of results from a genetic association analysis, and obtain
a list of genes with a high probability of mediating the GWAS signals in a particular tissue. The tools
also allows visualisation of the signals within a genetic region of interest.
The database and browser currently include the possibility of investigating colocalisation with liver [1]
and brain [24, 25] expression data, however the resource will soon be extended to include expression in
different tissues. This method, as well as alternative approaches for colocalisation testing [11, 13], are
also available with additional input options in an R package, coloc, from the Comprehensive R Archive
Network (http://cran.rproject.org/web/packages/coloc).
Discussion
We have developed a novel Bayesian statistical procedure to assess whether two association signals are
colocalised. The strength of this approach lies in its speed and analytical forms, combined with the fact
that it can use single variant p-values when only these are available. Our method differs from a typical
fine-mapping exercise in the sense that we are not interested in knowing which variant is likely to be
causal but only whether a shared causal variant is plausible.
Our results show that to provide an accurate answer to the colocalisation problem, high density
genotyping and/or accurate use of imputation techniques are key. The quality of the imputation is
another important parameter. Indeed, while the variance of the regression coefficient can be estimated
solely on the basis of the minor allele frequency for typed SNPs and sample size (and the case control ratio
in the case of a binary outcome) [15, 26], this ignores the uncertainty due to imputation. Filtering out
poorly imputed SNPs partially addresses this problem, with the drawback that it may exclude the causal
variant(s). Hence, providing estimates of the variance of the MLE, together with the effect estimates, will
result in greater accuracy. This additional option is available on the coloc package in R (http://cran.r-
project.org/web/packages/coloc).
We currently assume that each genetic variant is equally likely a priori to affect gene expression or trait.
A straightforward addition to our methodology would consider location specific priors for each variant,
which would depend for example on the distance to the gene of interest, or the presence of functional
elements in this chromosome region [27,28]. Our computation of the BF also assumes that, under H4, the
effect sizes of the shared variant on both traits are independent. This could be modified if, for example, one
compares eQTLs across different tissue types, or the same trait in two different studies. [29] has proposed
8a framework to deal with correlated effect sizes, and these ideas could potentially be incorporated in our
colocalisation test.
Another prior related issue is the choice of prior probabilities for the various configurations. For the
eQTL analysis, we used a 10−4 prior probability for a cis-eQTL. A more stringent threshold may be
better suited for trans-eQTLs where the variants are further away from the gene under genetic control.
We also used a prior probability of 10−4 for the lipid associations. Although our knowledge about this is
still lacking, this estimate has been suggested in the literature in the context of GWAS [18, 30, 31]. We
assigned a prior probability of 1× 10−6 for p12, which encodes the probability that a variant affects both
traits. It has been shown that SNPs associated with complex traits are more likely to be eQTLs compared
to other SNPs chosen at random from GWAS platforms [32], and a higher weighting for these SNPs has
been proposed when performing Bayesian association analyses [33, 34]. Also, eQTLs have been shown
to be enriched for disease-associated SNPs when a disease-relevant tissue is used [8, 35]. Our sensitivity
analysis for the p12 parameter showed broadly consistent results (Table S1). In cases where GWAS data
are available for both traits, [9] show that it is possible to estimate these parameters from the data using
a hierarchical model. This addition is a possible extension of our approach.
The interpretation of the posterior probabilities requires caution. For example, a low PP4 may not
indicate evidence against colocalisation in situations where PP3 is also low. It may simply be the result
of limited power, which is evidenced by high values of PP0, PP1 and/or PP2. Morever, a high PP4
is a measure of correlation, not causality. To illustrate this, one can consider the relatively common
situation where a single variant appears to affect the expression of several genes in a chromosome region
(as observed, for example, in the region surrounding the SORT1 gene). Several eQTLs will be colocalised,
both between them and with the biomarker of interest. In this situation one would typically expect that
a single gene is causally involved in the biomarker pathway but the colocalisation test with the biomarker
will generate high PP4 values for all genes in the interval.
We show that we can use conditional p-values to deal with multiple independent associations with
the same trait at one locus. While we found this solution generally effective, Wallace [13] points out that
this top SNP selection for the conditional analysis can create biases, although the bias is small in the
case of large samples and/or strong effects. For difficult loci with multiple associations for both traits
and available genotype data, it may be more appropriate to estimate Bayes factors for sets rather than
single variants in order to obtain an exact answer. This extension would avoid the issue of SNP selection
for the conditional analysis.
Importantly, GWAS signals can be explained by eQTLs only when the causal variant affects the
phenotype by altering the amount of mRNA produced, but not when the phenotype is affected by changing
the type of protein produced, although the former seems to be the most common [32]. Furthermore,
since many diseases manifest their phenotype in certain tissues exclusively [3, 19, 36, 37], colocalisation
results will be dependent on the expression dataset used. In addition to identifying the causal genes, the
identification of tissue specificity for the molecular effects underlying GWAS signals is a key outcome of
our method. We anticipate that building a reference set of eQTL studies in multiple tissues will provide
a useful check for every new GWAS dataset, pointing directly to potential candidate genes/tissue types
where these effects are mediated.
While this report focuses on finding shared signals between a biomarker dataset and a liver expression
dataset, we plan to utilise summary results of multiple GWAS and eQTL studies, for a variety of cell types
and traits. In fact, our method can utilise summary results from any association studies. Disease/disease,
(cis or trans) eQTL/disease or disease/biomarkers comparisons are all of biological interest and use the
same statistical framework. We expect that the fact that the test can be based on single SNP summary
statistics will be key to overcome data sharing concerns, hence enabling a large scale implementation of
this tool. The increasing availability of RNA-Seq eQTL studies will further increase the opportunity to
detect isoform specific eQTLs and their relevance to disease studies. Owing to the increasing availability
of GWAS datasets, the systematic application of this approach will potentially provide clues into the
9molecular mechanisms underlying GWAS signals and the aetiology of the disorders.
Materials and Methods
Expression dataset
We used in our analysis gene expression and genotype data from 966 human liver samples. The samples
were collected post-mortem or during surgical resection from unrelated European-American subjects
from two different non-overlapping studies, which have been described in [14]. The cohorts were both
genotyped using Illumina 650Y BeadChip array, and 39,000 expression probes were profiled using Agilent
human gene expression arrays. All of the expression data has been normalised as one unit even though
they were part of different studies, since high concordance between data generated using the same array
platforms has been previously reported. Probe sequences were searched against the human reference
genome GRCh37 from 1000genomes using BLASTN. Multiple probes mapping to one gene were kept
in order to examine possible splicing. The probes were kept and annotated to a specific gene if they
were entirely included in genes defined by Ensembl ID or by HGNC symbol using the package biomaRt
in R [38]. After mapping and annotating the probes, we were left with 40,548 mapped probes covering
24,927 genes.
Imputation of genetic data
Quality control filters were applied both before and after imputation. Before imputation, individuals
with more than 10% missing genotypes were removed, and SNPs showing a missing rate greater than
10%, a deviation for HWE at a p-value less than 0.001 were dropped. After imputation, monomorphic
SNPs were excluded from analyses.
To speed up the imputation process, the genome was broken into small chunks that were phased and im-
puted separately and then re-assembled. This was achieved using the ChunkChromosome tool
(http://genome.sph.umich.edu/wiki/ChunkChromosome), and specifying chunks of 1000 SNPs, with an
overlap window of 200 SNPs on each side, which improves accuracy near the edges during the phas-
ing step. Each chunk was phased using the program MACH1 (Versions 1.0.18, downloaded from:
http://www.sph.umich.edu/csg/abecasis/MACH/download/) with the number of states set to 300 and
the number of rounds of MCMC set to 20 for all chunks. Phased haplotypes were used as a basis
for imputation of untyped SNPs using the program Minimac (version 2011.10.27, downloaded from:
http://www.sph.umich.edu/csg/cfuchsb/minimac-beta-2012.8.15.tgz) with 1000 Genomes EUR reference
haplotypes (phase1 version 3, March 2012) to impute SNPs not genotyped on the Illumina array. The
data was then collated in probability format that can be used by the R Package snpStats [38].
eQTL analysis
eQTL p-values, effect sizes, and standard errors were obtained by fitting a linear trend test regression
between the expression of each gene and all variants 200 kilobases upstream and downstream from each
probe. After filtering out the variants with MAF < 0.001, monomorphic SNPs, multi-allelic SNPs (as
reported in 1000 Genomes or in the Ensembl database) and variants not sufficiently well imputed (Rsq
< 0.3, as defined by minimac http://genome.sph.umich.edu/wiki/minimac) between both datasets, we
applied our colocalisation procedure. We conducted conditional analysis on SNPs with p-values < 10−4
for the expression associations, and repeated the colocalisation test using expression data conditioned on
the most significant SNP. The aim of this analysis is to explore whether additional signals for expression
other than the main one are shared with the biomarker signal.
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Biomarker dataset
The biomarker p-values from the meta-analyses (with genomic control correction) were obtained from a
publicly available repository (http://www.sph.umich.edu/csg/abecasis/public/lipids2010/).
Posterior Computation
We call a “configuration” one possible combination of pairs of binary vectors indicating whether the vari-
ant is associated with the selected trait. We can group the configurations into five sets, S0, S1, S2, S3, S4,
containing assignments of all SNPs Q to the functional role corresponding to the five hypothesisH0,H1,H2,H3,H4.
We can compute the posterior probabilities for each of these 5 hypothesis using a Bayesian approach.
Firstly, we calculate the likelihood of each hypothesis,
L(Hh) = L(Hh | D) =
∑
S∈Sh
P (D | S)P (S) (1)
where P(S) is the prior probability of a configuration, P (D | S) is the probability of the observed data D
under a given configuration (which we will refer to as the likelihood of this configuration), and the sum
is over all configurations S which are consistent with a given hypothesis Hh, h=(1,2,3,4). Thus, each
configuration likelihood is weighted by the prior probability of that configuration.
Next, we compute the posterior probability by taking the ratio of the hypothesis likelihoods under the
different hypotheses. For example, the posterior probability under hypothesis 4 is:
PP4 =
L(H4)
L(H0) + L(H1) + L(H2) + L(H3) + L(H4)
(2)
If we also divide each probability by the baseline L(H0) we get:
PP4 =
L(H4)
L(H0)
1 + L(H1)L(H0) +
L(H2)
L(H0)
+ L(H3)L(H0) +
L(H4)
L(H0)
(3)
The ratios in the numerator and denominator of equation 3 are:
L(Hh)
L(H0)
=
∑
S∈Sh
P (D | S)
P (D | S0) ×
P (S)
P (S0)
(4)
The first ratio in this equation is a Bayes Factor (BF) for each configuration, and the second ratio is the
prior odds of a configuration compared with the baseline configuration S0. The BF can be computed for
each variant from the p-value, or estimated regression coefficient βˆ and variance of βˆ, using Wakefield’s
method. By summing over all configurations in Sh we are effectively comparing the support in the data
for one alternative hypothesis versus the null hypothesis.
Bayes factor computation
A Bayes Factor for each SNP and each trait 1 and 2 was computed using the Approximate Bayes Factor
(ABF, [18]). Wakefield’s method yields a Bayes factor that measures relative support for a model in
which the SNP is associated with the trait compared to the null model of no association.
The equation used is the following:
ABF =
1√
1− r × exp
[
−Z
2
2
× r
]
(5)
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where Z = βˆ/
√
V is the usual Z statistic and the shrinkage factor r is the ratio of the variance of the
prior and total variance (r = W/(V +W )).
Assuming a normal distribution, the p-value of each SNP can be converted to standard one-tailed Z-score
by using inverse normal cumulative distribution function. So for a SNP, all that it is needed are the
p-values from a standard regression output, and
√
W , the standard deviation of the normal prior N(0,W)
on β.
The variance of the effect estimate, V, can be approximated using the MAF and sample size. However
for imputed data it is preferable to use the variance outputted in standard regression analysis directly
in the ABF equation. For the expression dataset used here, the variance and effect estimates from the
regression analysis were used for computation of ABFs. More details can be found in the Supplementary
materials.
Choice of priors
Prior probabilities are assigned at the SNP level and correspond to mutually exclusive events. We assigned
a prior of 1× 10−4 for p1 and p2, the probability that a SNP is associated with either of the two traits.
Since all SNPs are assumed to have the same prior probability of association, this prior can be interpreted
as an estimate for the proportion of SNPs that we expect to be associated with the trait in question.
We also assigned a prior probability of 1 × 10−6 for p12, the probability that one SNP is associated
with both traits. This probability can be better understood when it is re-expressed as the conditional
probability of a SNP being associated with trait 2, given that it is associated with trait 1. So assigning a
probability of 1× 10−6 means that 1 in 100 SNPs that are associated with trait 1 is also associated with
the other. As a sensitivity analysis, we ran the comparison with Teslovich et al. using two other prior
probabilities for p12, p12 = 2× 10−6 which means 1 in 50 SNPs that are associated with one trait is also
associated with the other; and p12 = 10
−5 which means 1 in 10 SNPs.
To compute the ABF, we also needed to specify the standard deviation for the prior, and we set this to
0.20 for binary traits and 0.15 for quantitative traits (more details in Supplementary).
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Figure 1. Example of one configuration under different hypotheses represented by one
binary vector for each trait of (0, 1) values of length n = 8, the number of shared variants
in a region. The value of 1 means that the variant is causally involved in disease, 0 that it is not. The
first plot shows the case where only one dataset shows an association. The second plot shows that the
causal SNP is different for the biomarker dataset compared to the expression dataset. The third plot
shows the configuration where the single causal variant is the fourth one.
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Figure 2. Illustration of the colocalisation results. Negative(A-B, FRK gene and LDL, PP3 >
90%) and positive (C-D, SDC1 gene and total cholesterol, PP4 > 80%) colocalisation results. -log10(p)
association p-values for biomarker (top, A and C) and -log10(p) association p-values for expression
(bottom, B and D) at the FRK (A, B) and SDC1 locus (C, D), 1Mb range.
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Figure 3. Simulation analysis with a shared causal variant between two studies: one eQTL
(sample size 966 samples, 10% of the variance explained by the variant) and one
biomarker (such as LDL). The variance explained by the biomarker is colour coded and the x-axis
shows the sample size of the biomarker study. The y axis shows the median, 10% and 90% quantile of
the distribution of PP4 values (which supports a shared common variant).
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Figure 4. Simulation analysis with a shared causal variant between two studies: one eQTL
(sample size 966 samples) and one biomarker (sample size of 4,000 samples). The variance
explained by the biomarker and the expression is the same and is colour coded. The x-axis shows the
estimated PP4 for 1,000 simulations using data imputed from metaboChip Illumina array. The y-axis
uses the same dataset restricted to variants present on the Illumina 660W genotyping array to assess
the impact of a lower variant density. A. The causal variant is included in the Illumina 660W panel. B.
The causal SNP not included in Illumina 660W panel.
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Figure 5. Summary of proportional and Bayesian colocalisation analysis of simulated data.
Each plot shows a different scenario, the total number of causal variants in a region is indicated by
number of circles in the plot titles with causal variants affecting both traits, the eQTL trait only, or the
biomarker trait only, indicated by full circles, top-shaded circles and bottom-shaded circles respectively.
In the top row the causal variant is typed or imputed, whereas only tag variants are typed/imputed in
the bottom row. For proportional testing (under the BMA approach), we show the proportion of
simulations with posterior predictive P-value p < 0.05 (black horizontal line) while for our Bayesian
analysis we plot the proportion of simulations with the posterior probability (PP3 or PP4) of the
indicated hypothesis > 0.9. Error bars show 95% confidence intervals (estimated based on an average of
1,000 simulations per scenario). In all cases, for the eQTL sample size is 1,000; genetic variants explain
a total of 10% of eQTL variance; for the biomarker trait, the sample size is 10,000.
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Figure 6. LDL association and eQTL association plots at the SYPL2 locus. The x-axis shows
the physical position on the chromosome (Mb) A: -log10(p) association p-values for LDL. The p-values
are from the Teslovich et al published meta-analysis of > 100,000 individuals. B: -log10(p) association
p-values for SYPL2 expression in 966 liver samples. C: -log10(p) association p-values for SYPL2
expression conditional on the top eQTL associated SNP at this locus (rs2359653).
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Tables
Table 1. Loci previously reported to colocalise with liver eQTL, but not supported by our
analysis
Chr Region Gene Trait Biom pval Biom SNP eQTL pval eQTL SNP Primary signal Secondary signal* Other genes colocalising in region (PP4 > 75%)
PP3 (%) PP4 (%) PP4 (%) conditional SNP
1 109824678:110224737 SYPL2 LDL 9.7e-171 rs629301 7.1e-103 rs2359653 > 99 < 1 99 rs2359653 SORT1/CELSR2/PSRC1/PSMA5
TC 8.0e-52 rs672569 7.1e-103 rs2359653 > 99 < 1 99 rs2359653 SORT1/CELSR2/PSRC1/PSMA5
2 27467244:27867303 IFT172 TG 5.7e-133 rs1260326 1.7e-130 rs704791 > 99 < 1 C2orf16/GCKR
TC 7.3e-27 rs1260326 1.7e-130 rs704791 > 99 < 1 C2orf16/GCKR
6 116062804:116462863 FRK LDL 2.9e-09 rs11153594 6.6e-15 rs195517 99 1
TC 1.7e-10 rs9488822 6.6e-15 rs195517 94 6
17 45589357:45989416 TBKBP1 LDL 1.1e-07 rs8072100 2.1e-21 rs9913503 87 9 KPNB1
TC 1.8e-07 rs8072100 2.1e-21 rs9913503 92 2 KPNB1
19 45248464:45648523 APOC4 TG 1.1e-30 rs439401 1.1e-299 19:45452692:A AG > 99 < 1 96 19:45452692:A AG
20 34013995:34414054 CPNE1 TC 3.8e-10 rs2277862 7.3e-110 rs6060524 > 99 < 1
Gene/eQTL associations previously reported as having a probable shared variant but not supported by
our method based on PP3 (posterior probability for distinct signal values) > 75%. *Secondary signals
are reported only when there is a secondary eQTL at a p-value greater than 10−4. Colocalisation tests
are computed using the expression data conditioned on the listed SNP. Other genes in the same region
as the gene listed that colocalise using our method are reported.
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Table 2. Novel loci not previously reported to colocalise with liver eQTL, but colocalising
based on our analysis
Chr Region Gene Trait PP.H3.abf PP.H4.abf Reference
2 20201795:20601854 SDC1 TC 17 82 [39]
2 85349026:85749085 TGOLN2 HDL 17 83 [40]
2 120908798:121308857 INHBB LDL 7 77 [41]
3 32322873:32722932 CMTM6 TC 8 77
6 34355095:34755154 C6orf106 TC 15 85
8 59158506:59558565 UBXN2B LDL 13 87 [42]
TC 15 85
9 2454062:2854121 VLDLR LDL 1 91 [43]
10 17079389:17479448 VIM TC 5 93 [44]
10 94637063:95037122 CYP26A1 TG 3 95 [45]
12 111508189:111908248 CUX2 HDL 2 89
LDL 2 98
TC 2 98
15 96517293:96917352 ENSG00000259359 HDL 2 87
16 56310220:56710279 OGFOD1 TC 7 84 [46]
16 71894416:72310900 HP LDL 1 97 [47]
TC 1 97
TG 2 75
HPR LDL 1 99 [48]
TC 1 99
TG 2 89
22 46433083:46833138 PPARA TC 10 81 [49]
Signals not reported by Teslovich et al. with PP4 > 75% for colocalisation between the liver eQTL
dataset and the Teslovich meta-analysis of LDL, HDL, TG, TC, using the strict prior p12 = 10
−6. For
11 genes with strong candidate status for lipid metabolism, we list a key reference that describes their
function.
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Supplementary material
Simplified model under assumption that all SNPs have the same prior
The probability space for a single SNP can be fully partitioned into (p0, p1, p2, p12), where p0 is the prior
probability that a SNP is not associated with either trait, p1 is defined as the prior probability that the
SNP is only associated with trait 1, p2 the prior probability that the SNP is associated only with trait 2,
while p12 is the prior probability that the SNP is associated with both traits. We therefore have:
p0 + p1 + p2 + p12 = 1
The priors p0, p1, p2, p12 can vary across SNPs, for example depending on MAF, a measure of imputation
quality, proximity to the promoter, function of the SNP. If however the priors do not vary across SNPs,
then equation 1 in the main text becomes:
L(Hh) = L(Hh | D) =
∑
S∈Sh
P (D | S)P (S) = P (S | S ∈ Sh)×
∑
S∈Sh
P (D | S) (1)
This simplification is possible because each binary vector that belongs to the same set Sh has the same
prior probability.
The prior probability of any one configuration in the different sets is:
• If S ∈ S0, then P (S) = pQ0
• If S ∈ S1, then P (S) = pQ−10 × p1
• If S ∈ S2, then P (S) = pQ−10 × p2
• If S ∈ S3, then P (S) = pQ−20 × p1 × p2
• If S ∈ S4, then P (S) = pQ−10 × p12
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2Because we condition our analysis on having at most one association per trait, these probabilities should
be normalised: P (S) = pQ0 /C, where C is the sum of the probabilities associated with all the assignments
that contain at most one association per trait. However, because subsequent derivations only consider
the ratio of probabilities, the C term cancels out and this normalisation becomes unnecessary. Dividing
each of these probabilities by P (S0) to obtain the ratio of prior odds, and since p0 ≈ 1, the second terms
in equation 4 in the main text becomes:
• If S ∈ S0, then P (S)P (S0) =
pQ0
pQ0
= 1
• If S ∈ S1, then P (S)P (S0) =
pQ−10
pQ0
× p1 = p1p0 ≈ p1
• If S ∈ S2, then P (S)P (S0) =
pQ−10
pQ0
× p2 = p2p0 ≈ p2
• If S ∈ S3, then P (S)P (S0) =
pQ−20
pQ0
× p1 × p2 = p1p0 ×
p2
p0
≈ p1 × p2
• If S ∈ S4, then P (S)P (S0) =
pQ−10
pQ0
× p12 = p12p0 ≈ p12
To compute the first terms in equation 4 in the main text, the BFs for each configuration in a set, we
make use of the ABF derived for each SNP-trait association (section below). Two key assumptions are
necessary for the following computations. Firstly that the traits are measured in unrelated individuals,
and secondly that the effect sizes for the two traits are independent.
Putting the two terms together, we have:
• L(H0)/L(H0) = 1
• L(H1)/L(H0) = p1 ×
∑Q
j=1ABF
1
j
• L(H2)/L(H0) = p2 ×
∑Q
j=1ABF
2
j
• L(H3)/L(H0) = p1 × p2 ×
∑
j,k,j 6=k ABF
1
j ABF
2
k
• L(H4)/L(H0) = p12 ×
∑Q
j=1ABF
1
j ×ABF 2j
Of note, we can also write:
L(H3)/L(H0) = p1 × p2 ×
Q∑
j=1
ABF 1j
Q∑
j=1
ABF 2j −
[
p1 × p2
p12
× L(H4)/L(H0)
]
Bayes factor computation
We assume that summary statistics for each SNP in the two datasets were obtained by fitting a generalised
linear model with the phenotype as dependent variable and SNP genotype call as independent variable:
Y = µ+ βX
The Bayes factor quantities are estimated from summary statistics using the Asymptotic Bayes Factor
derivation [1]. Using Wakefield’s notations, under the null we assume that the effect size β = 0. Under
the alternative, β is normally distributed with mean 0 and variance W .
3To derive the ABF computation, Wakefield uses the fact that asymptotically βˆ → N(β, V ). The distri-
bution of the estimated regression parameters µˆ and βˆ is:
[
µˆ
βˆ
]
∼ Np+1
([
µ
β
] [
Iµµ Iµβ
ITµβ Iββ
]−1)
(2)
The intercept µ is a nuisance parameter which we can remove using the transformation:
γ = µ+
Iµβ
Iµµ
β
In which case the previous equality becomes:
[
γˆ
βˆ
]
∼ Np+1
([
γ
β
] [
I∗µµ 0
0T Iββ
]−1)
(3)
This independence property can be combined with independent priors for both parameters so that one
can only consider β and ignore the effect of the µ term. Hence, after applying the reparameterisation we
have:
BF =
∫
f(β)
f(0)
pi(β)dβ
Which then becomes (assuming normality and asymptotic behaviour):
ABF =
1√
1− r × exp
[
−Z
2
2
× r
]
where Z = βˆ/
√
V is the Wald test statistic. The shrinkage factor r is the ratio of the variance of the prior
and total variance (r = W/(V +W )). This ratio takes a value between 0 and 1 and measure the relative
contributions of the prior (W) and likelihood (V) to the inference. Values of r closer to 1 indicate a larger
contribution from the likelihood (i.e. the data). The asymptotic posterior distribution of β is N(rβˆ, rV ).
As the sample size increases, V → 0 and r → 1, so that the posterior concentrates around the MLE. We
can compute the Z statistic from the p-values of a standard regression output using |z| = Φ−1(1− p/2),
where Φ−1 is the inverse normal cumulative. Otherwise we can compute the Wald statistics directly if
the estimated regression coefficients βˆ and their variances var(βˆ) are supplied.
Variance of the estimated effect size V ar(βˆ) = V
The variance of the maximum likelihood estimate βˆ (denoted by V ) can be approximated using the allele
frequency of the variant f , the sample size N and the case control ratio s for binary outcome. It is well
established that the score statistic to test whether the effect size β = 0 is:
U =
∑
i
(Yi − Y¯ )Xj
Score test theory asserts that the variance of U under the null is the inverse of the variance of the
estimated effect size βˆ, also under the null. V ar(U) under the null can be estimated in several ways,
including the standard derivation of the Fisher information matrix [2].
4We assume that the genotypes X are under Hardy Weinberg equilibrium. Hence X is drawn from a
binomial distribution with success parameter f, which we use to denote the allele frequency.
V ar[Xj ] = 2fj(1− fj)
where fj is the population allele frequency of the SNP j.
When the dataset is a case-control (the trait Y is binomial):
V ar[Y ] = s(1− s)
where s is the proportion of cases in the population. If the outcome variable Y is continuous we assume
that Y is normalised such that V ar(Y ) = 1.
Putting together these equations, we have, in a case control setting:
V = V ar(βˆj) =
1
Ns(1− s)× 2fj(1− fj)
Choice of priors for the probability that each variant affects the traits
The prior probabilities assigned to each SNP, p0, p1, p2, p12, are mutually exclusive events. The probability
of a SNP being associated with both traits, p12, can be interpreted using a conditional argument:
p12 = P(SNP associated with both traits)
= P(SNP associated with trait 1)× P(SNP associated with trait 2 | SNP associated with trait 1)
The conditional term in the right hand side of the equation above can be approximated as follows:
P(SNP associated with trait 2 | SNP associated with trait 1) = p12
(p12 + p1)
=
10−6
(10−6 + 10−4)
≈ 10
−6
10−4
≈ 0.01
So in terms of conditional probability, if we assume a prior probability of p12 = 1× 10−6 and p1 = p2 =
1× 10−4, then the prior assumption is that of all SNPs associated with trait 1, 1 in 100 of them will also
be associated with trait 2. Since as we stated previously each SNP belongs to only one of the five sets
corresponding to the five hypotheses, the probability of a SNP not being associated with either trait is:
p0 = 1− (p1 + p2 + p12) ≈ 0.9998 ≈ 1.
Choice of priors for the standard deviation W of the effect size parameter β
Prior standard deviation of the additive effect parameter β was set to 0.15 for a continuous trait. Owing
to our assumption that V ar(Y ) = 1, this prior corresponds to a variance explained of ∼ 0.01 for a variance
with MAF of 30%.
5In a case-control study, we set W = 0.2 for the variance of the log-odds ratio parameter, as was previously
used in WTCCC [3], which corresponds to an inter-quartile range between 0.74 and 1.35 for the odds
ratio parameter. The priors chosen for case-control and for quantitative traits are also very similar to
the SNPTEST default ( [4, 5]).
Simulation procedure
To simulate the posterior probability of a common signal (“PP4”) under different scenarios, we used the
imputed genotypes from two different datasets: Whitehall II study (WHII), a longitudinal prospective
cohort study genotyped using the gene-centric Illumina Metabochip [6, 7], and the expression dataset
described herein. We randomly chose a causal SNP A among genotyped and well imputed SNPs (Rsq >
0.8) from any genomic region in common between the two datasets.
The additive genetic variance explained by the locus is
V ar[βXA] = β
2
A × 2fA(1− fA)
where fA is the population allele frequency of the causal SNP A, and βA is the additive effect (in standard
deviations) [8].
For different variance explained for the causal SNP , depending on the simulation scenario, we computed
the true effect at the causal SNP:
βA =
√
V ar[βXA]
2fA(1− fA)
We then simulated the phenotype of the ith individual in each of the two datasets using the computed
true effect βA:
Yi = xiA × βA + ei with ei ∼ N(0, 1)
where xiA is the additive genetic value at the causal SNP of individual i and ei is a random error drawn
from a normal distribution with mean 0 and variance of 1.0.
To simulate p-values from different sample sizes using the original datasets, we computed the expected
value of each estimated beta multiplying the pairwise correlation coefficient r between the causal SNP A
and all other SNPs, by the true value of beta at the causal SNP:
The derivation of this equation is described in the following section.
The expected regression coefficient at a second SNP B in relation to the causal SNP A is then:
βj = βA r
√
fA(1− fA)
fj(1− fj) . (4)
where fj is a vector or βs for all SNPs excluding the causal SNP.
The difference between the regression coefficients βˆ estimated from the glm and the expected value β,
computed at each SNP, can be considered the standard error of the mean and it varies with 1√
(N)
,
where N is the original sample size. When N is increased, the estimate becomes closer to the true value
β, decreasing the variability of the estimator. Then the simulations with a larger sample size involves
simply rescaling this difference:
6(βˆ − β)
√
N
N.new
(5)
Then we can compute the new p-values from the new simulated estimates and standard deviations. We
used this method to perform simulations to find sample size required for colocalisation analysis, and to
find the consequence of using limited variant density.
Relationship between model parameters and LD
Equation 4 was first derived in [9], where the additive effects for case-control studies were shown to decay
linearly, in proportion to r, the correlation between the causal and marker loci. Here we show the same
relationship holds for quantitative traits.
We use the same LD model, and associated notation, as defined in [9]. To summarise briefly, let A and B
be a pair of biallelic SNPs, with the alleles at each coded by 0 and 1. Let fA be the population frequency
of allele 1 at SNP A, and define fB similarly for SNP B. Let r be the population correlation coefficient
between them, the square of which is a commonly used measure of LD. We can define the following
conditional probabilities on a haplotype level:
q0 = P (A = 1 | B = 0) ,
q1 = P (A = 1 | B = 1) ,
These quantities were shown to be related by the identity,
r = (q1 − q0)
√
fB(1− fB)
fA(1− fA) ,
Let SNP A be a causal and SNP B be a marker. Define the following expectations:
a0 = E(Y | A = 0) , b0 = E(Y | B = 0) ,
a1 = E(Y | A = 1) , b1 = E(Y | B = 1) ,
a2 = E(Y | A = 2) , b2 = E(Y | B = 2) .
Relating these using the LD model gives,
b0 = a0(1− q0)2 + a12q0(1− q0) + a2q20 ,
b1 = a0(1− q0)(1− q1) + a1 (q0(1− q1) + q1(1− q0)) + a2q0q1 ,
b2 = a0(1− q1)2 + a12q1(1− q1) + a2q21 .
Combining and rearranging these gives,
b21 − b0b2 =
(
a21 − a0a2
)
(q1 − q0)2 .
If we consider an additive model, it is easy to show that b21 − b0b2 = β2B and a21 − a0a2 = β2A. Putting
these together gives,
βB = βA r
√
fA(1− fA)
fB(1− fB) . (6)
7Equation 6 is analogous to the respective results from [9] for binary traits. The main difference is that
for quantitative traits here we have shown them to be exact. As before, we can see that the deviation
effect decays more quickly with LD than does the additive effect: quadratically in r rather than linearly.
This implies that the distortion effect described earlier for binary traits will extend also to quantitative
traits.
Relationship between model parameters and LD using imputed
genotypes
The previous section assumed the genotypes were observed without error. We can derive a similar
relationship in the scenario where we instead use imputed genotype data.
Continuing with the same notation, we now allow A and B to have posterior distributions for each
individual’s genotype. The appropriate analysis should average the likelihood over these posteriors. A
convenient approximation to this is to replace each genotype by its mean posterior value. [10] showed
that this is a good approximation in the GWAS context. This leaves us in a similar situation as before,
except that A and B have become continuous quantitative variables. The following general results apply
for the regression parameters,
βA =
cov(Y,A)
var(A)
,
βB =
cov(Y,B)
var(B)
.
We need two assumptions to complete the derivation. Firstly, we require that Y and B are conditionally
independent given A. In other words, cov(Y,B | A) = 0. This is implicit in the definition of SNP A
being the causal SNP, and is also implicitly assumed in the definitions in the previous section. The only
extension here is that we assume this relationship still holds after imputation. This allows us to simplify
the covariance of Y and B using the law of total covariance,
cov(Y,B) = E(cov(Y,B | A)) + cov(E(Y | A),E(B | A))
= E(0) + cov(E(Y | A),E(B | A))
= cov(E(Y | A),E(B | A)) .
The second assumption we need is that the conditional expectations of Y and B on A are both linear in
A. That is,
E(Y | A) = θY 0 + θY 1A ,
E(B | A) = θB0 + θB1A .
We already make this assumption for the relationship between Y and A, in using a linear regression
model for the trait. The extra part here is that we assume the same type of relationship between the
causal SNP and marker SNP. Since the underlying values for A and B are binary, this is reasonable.
Note that these are just standard linear regression equations, so we have that,
θY 1 =
cov(Y,A)
var(A)
,
θB1 =
cov(B,A)
var(A)
.
8Putting all of these formulae together gives,
cov(Y,B) = cov(E(Y | A),E(B | A))
= cov(θY 1A, θB1A)
= θY 1θB1 cov(A,A)
=
cov(Y,A) cov(B,A)
var(A)
.
Dividing both sides by var(B) gives,
cov(Y,B)
var(B)
=
cov(Y,A)
var(A)
cov(B,A)
var(B)
cov(Y,B)
var(B)
=
cov(Y,A)
var(A)
cov(B,A)√
var(A) var(B)
√
var(A)
var(B)
βB = βA cor(B,A)
√
var(A)
var(B)
βB = βA r
√
var(A)
var(B)
.
This formula is analogous to equation (6). Note that if A and B are observed without error then we
recover the previous formula.
Simulations to find sample size required for colocalisation analysis
We used the simulation method described above to compare the distribution of PP4 of randomly sampled
regions under different scenarios. We used the original sample size of the eQTL dataset (n=966) and a
variance explained of 10% for expression, while varying the sample size of the biomarker dataset and the
proportion of the biomarker’s variance explained by the causal variant.
Simulations to find consequence of using limited variant density
We compared the PP4 of randomly sampled regions, using the simulation procedure described above,
with the PP4 of the same regions after filtering for only the SNPs present in the Illumina 660K Chip
(Figures S1 and S2). The original dataset based on > 990genomes imputed data will be much denser
than the Illumina dataset. This way we can consider the consequences of having imputed data versus
genotyped data.
The same procedure is used to simulate the case when the causal SNP is not included in the data by
excluding the causal SNP only from the Illumina dataset. All analyses were conducted in R [11].
Simulations for comparison with existing colocalisation tests
For simulations comparing proportional and Bayesian approaches, we sampled, with replacement, hap-
lotypes of SNPs with a minor allele frequency of at least 5% found in phased > 990 Genomes Project
data [12] across all 49 genomic regions outside the major histocompatibility complex (MHC) which have
9been identified as type 1 diabetes (T1D) susceptibility loci to date, as summarised in T1DBase (Figures
S3 and S4). [13]. These represent a range of region sizes and genomic topography typical of GWAS hits.
We excluded the MHC region which is known to have high variation, strong LD and exhibits huge genetic
influence on autoimmune disease risk involving multiple loci and hence requires individual treatment in
any GWAS [14]. For each trait, we selected one or two “causal variants” at random, and simulated
a Gaussian distributed quantitative trait for which each causal variant SNP explains a specified pro-
portion of the variance. We either used all SNPs or the subset of SNPs which appear on the Illumina
HumanOmniExpress genotyping array to conduct colocalisation testing to reflect the scenarios of very
dense targeted genotyping versus a less dense GWAS chip. All analyses were conducted in R [11] using
the coloc package for proportional colocalisation testing.
10
Supplementary Figures and Tables
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Figure S1. Simulation analysis with a shared causal variant between two studies, one
eQTL (sample size 966 samples) and one biomarker, comparing results using imputed
versus not imputed data where the causal SNP is included in both the cases. Each plot
shows different sample sizes for one dataset. The variance explained by the causal variant for both the
traits is colour coded. The x-axis shows the estimated PP4 for 1,000 simulations using data imputed
from metaboChip Illumina array (Methods). The y-axis uses the same dataset restricted to variants
present on the Illumina 660W genotyping array to assess the impact of a lower variant density. The
causal variant is included in the Illumina 660W panel.
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Figure S2. Simulation analysis with a shared causal variant between two studies, one
eQTL (sample size 966 samples) and one biomarker, comparing results using imputed
versus not imputed data where the causal SNP is not included in one of the datasets. Each
plot shows different sample sizes for one dataset. The variance explained by the causal variant for both
the traits is colour coded. Column and row headings are the same as in previous figure. The causal
SNP is not included in Illumina 660W panel.
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Figure S3. The relationship between PP4 and the posterior predictive p-value (on a
-log10 scale) from proportional testing. Proportional testing uses the BMA approach,
integrating over all possible two SNP models. Each row shows a different scenario, the total
number of causal variants in a region is indicated by number of symbols in the plot titles with the
type of causal variant indicated by the symbol: full circle - affects both traits; top only - affects
one trait; bottom only- affects other trait. For proportional testing, the grey vertical line indicates
the threshold ppp of 0.05. Each column shows the total proportion of trait variance for the
biomarker explained by all variants in a region, with variance explained spread equally over all
variants. In all cases, for the eQTL trait, n=1,000, 10% of the variance explained by the variant;
for the biomarker trait, n=10,000.
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Figure S4. The relationship between PP4 and the posterior predictive p-value (on a
-log10 scale) from proportional testing, using subset of SNPs which appear on the
Illumina HumanOmniExpress genotyping array. For the eQTL trait, n=1,000, 10% of the
variance explained by the variant; for the biomarker trait, n=10,000, 1% or 2% of the variance
explained by the variant. Column and row headings are the same as in previous figure.
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Figure S5. Regional Manhattan plots with −log10 p-value for loci reported in
Teslovich et al. [15] as having a probable shared variant but not supported by our
method based on PP4 (posterior probability for a shared signal values) < 75%. The
plots focus on a specific region of the genome with a range of ∼ 400 kilobases around the
expression probe of the gene specified below each plot. The top plots use the -log10(p-value) from
the published meta-analysis with one of the four lipid biomarkers; the bottom plots show the
-log10(p-value) computed by fitting a generalized linear model with expression as dependent
variable and SNP genotypes as independent variable. Each dot represents one SNP, imputed or
directly typed. The value on the top of each plot shows the PP4 from the colocalisation test
between the two top SNP of the expression and biomarker associations.
Table S1. Results using reported loci that colocalise with liver eQTL
geneTranscriptsymbol TranscriptPvalueTesl Trait Chr Region Biom pval Biom SNP eQTL pval eQTL SNP Best Causal p12 = 10
−5 p12 = 2 × 10−6 p12 = 10−6
PP3 (%) PP4 (%) PP3 (%) PP4 (%) PP3 (%) PP4 (%)
RHCE 7.00E-54 LDL,TC NA NA NA NA NA NA NA NA NA NA NA NA NA
RHD 4.00E-08 LDL 1 25428038:25828097 1.20E-10 rs12027135 7.70E-11 rs909832 rs12027135 9 91 33 67 50 50
1 25456834:25856893 1.20E-10 rs12027135 0.0087 rs909832 rs12027135 < 1 2 < 1 < 1 < 1 < 1
TC 1 25428038:25828097 4.10E-11 rs12027135 7.70E-11 rs909832 rs12027135 9 91 33 67 50 50
1 25456834:25856893 4.10E-11 rs12027135 0.0087 rs909832 rs12027135 < 1 2 < 1 < 1 < 1 < 1
TMEM50A 4.00E-08 LDL 1 25488669:25888728 1.20E-10 rs12027135 4.40E-11 rs9689 rs3091242 12 88 41 59 58 42
TC 1 25488669:25888728 4.10E-11 rs12027135 4.40E-11 rs9689 rs3091242 13 87 43 57 60 39
TMEM57 2.00E-145 LDL 1 25626305:26026364 1.20E-10 rs12027135 2.10E-31 rs873308 rs12027135 1 99 5 94 10 90
1 25624780:26024839 1.20E-10 rs12027135 6.40E-08 rs686631 rs10903129 2 98 9 90 17 82
1 25625807:26025866 1.20E-10 rs12027135 7.60E-223 rs873308 rs873308 2 97 11 88 21 79
TC 1 25626305:26026364 4.10E-11 rs12027135 2.10E-31 rs873308 rs12027135 1 99 5 94 11 89
1 25624780:26024839 4.10E-11 rs12027135 6.40E-08 rs686631 rs12027135 2 98 9 90 17 82
1 25625807:26025866 4.10E-11 rs12027135 7.60E-223 rs873308 rs873308 3 97 15 85 26 74
ANGPTL3 1.00E-13 LDL 1 62870388:63270447 2.60E-18 rs3850634 1.90E-15 rs636497 rs3850634 9 91 34 66 51 49
TC 1 62870388:63270447 4.90E-41 rs3850634 1.90E-15 rs636497 rs3850634 9 90 34 65 51 49
TG 1 62870388:63270447 8.80E-43 rs2131925 1.90E-15 rs636497 rs2131925 8 92 29 70 45 54
DOCK7 1.00E-22 LDL 1 62849818:63249877 2.60E-18 rs3850634 1.90E-25 rs11485618 rs3850634 5 95 23 77 37 63
1 62720869:63120928 2.60E-18 rs3850634 0.0049 rs10458569 rs3850634 1 13 2 3 2 1
TC 1 62849818:63249877 4.90E-41 rs3850634 1.90E-25 rs11485618 rs10789118 5 95 20 80 33 67
1 62720869:63120928 4.90E-41 rs3850634 0.0049 rs10458569 rs3850634 1 14 2 3 2 1
TG 1 62849818:63249877 8.80E-43 rs2131925 1.90E-25 rs11485618 rs2131925 5 94 23 77 37 63
1 62720869:63120928 8.80E-43 rs2131925 0.0049 rs10458569 rs2131925 1 14 2 3 2 2
CELSR2 5.00E-94 LDL 1 109618271:110018330 9.70E-171 rs629301 1.50E-120 rs646776 rs629301 < 1 > 99 1 99 2 98
TC 1 109618271:110018330 5.80E-131 rs629301 1.50E-120 rs646776 rs629301 < 1 > 99 1 99 3 97
PSMA5 9.00E-17 LDL 1 109744528:110144587 9.70E-171 rs629301 1.50E-17 rs599839 rs629301 < 1 99 4 96 7 93
1 109741904:110141963 9.70E-171 rs629301 1.20E-07 rs600806 rs629301 98 1 99 < 1 99 < 1
TC 1 109744528:110144587 5.80E-131 rs629301 1.50E-17 rs599839 rs629301 < 1 99 3 97 7 93
1 109741904:110141963 5.80E-131 rs629301 1.20E-07 rs600806 rs629301 98 1 99 < 1 99 < 1
PSRC1 2.00E-271 LDL 1 109622208:110022267 9.70E-171 rs629301 1.10E-299 rs7528419 rs629301 < 1 99 3 97 7 93
TC 1 109622208:110022267 5.80E-131 rs629301 1.10E-299 rs7528419 rs629301 < 1 99 3 96 7 93
SORT1 2.00E-300 LDL 1 109652373:110052432 9.70E-171 rs629301 1.10E-299 rs7528419 rs629301 < 1 > 99 3 96 7 93
1 109656429:110056488 9.70E-171 rs629301 1.10E-299 rs7528419 rs629301 < 1 > 99 3 96 7 93
TC 1 109652373:110052432 5.80E-131 rs629301 1.10E-299 rs7528419 rs629301 < 1 > 99 3 96 7 93
1 109656429:110056488 5.80E-131 rs629301 1.10E-299 rs7528419 rs629301 < 1 > 99 3 96 7 93
SYPL2 1.00E-23 LDL 1 109824678:110224737 2.20E-64 rs672569 7.10E-103 rs1933182 rs1933182 > 99 < 1 > 99 < 1 > 99 < 1
1 109821999:110222054 2.90E-168 rs599839 0.0031 rs7536292 rs599839 < 1 < 1 < 1 < 1 < 1 < 1
TC 1 109824678:110224737 8.00E-52 rs672569 7.10E-103 rs1933182 rs1933182 > 99 < 1 > 99 < 1 > 99 < 1
1 109821999:110222054 4.10E-130 rs599839 0.0031 rs7536292 rs599839 < 1 < 1 < 1 < 1 < 1 < 1
IFT172 7.00E-32 TC 2 27467244:27867303 7.30E-27 rs1260326 1.70E-130 rs704791 rs704791 > 99 < 1 > 99 < 1 > 99 < 1
TG 2 27467244:27867303 5.70E-133 rs1260326 1.70E-130 rs704791 rs1260326 > 99 < 1 > 99 < 1 > 99 < 1
SLC39A8 3.00E-19 HDL 4 102982958:103383017 7.20E-11 rs13107325 3.80E-21 rs13107325 rs13107325 < 1 > 99 < 1 > 99 < 1 > 99
4 102972446:103372505 7.20E-11 rs13107325 0.027 rs11733483 rs13107325 < 1 < 1 < 1 < 1 < 1 < 1
HLA-DQB1 2.00E-13 TC 6 32427977:32828028 2.60E-17 rs17533167 2.10E-43 rs3129720 rs3129720 > 99 < 1 > 99 < 1 > 99 < 1
HLA-DRB1 7.00E-44 TC 6 32346553:32746610 4.00E-19 rs3177928 1.90E-217 rs477515 rs477515 > 99 < 1 > 99 < 1 > 99 < 1
FRK 4.00E-12 LDL 6 116062804:116462863 2.90E-09 rs11153594 6.60E-15 rs195517 rs195517 90 10 98 2 99 1
TC 6 116062804:116462863 1.70E-10 rs9488822 6.60E-15 rs195517 rs9488822 61 39 89 11 94 6
PPP1R3B 1.00E-14 LDL 8 8795514:9195573 7.40E-15 rs2126259 6.20E-17 rs2126259 rs2126259 < 1 > 99 2 98 4 96
8 8793929:9193988 7.40E-15 rs2126259 1.90E-17 rs4240624 rs9987289 1 99 5 94 10 89
TC 8 8795514:9195573 9.00E-24 rs2126259 6.20E-17 rs2126259 rs2126259 < 1 > 99 2 98 3 97
8 8793929:9193988 9.00E-24 rs2126259 1.90E-17 rs4240624 rs2126259 1 98 8 92 14 85
HDL 8 8793929:9193988 6.40E-25 rs9987289 6.20E-17 rs2126259 rs9987289 < 1 > 99 2 98 4 96
8 8795514:9195573 6.40E-25 rs9987289 1.90E-17 rs4240624 rs9987289 1 98 7 93 14 86
TTC39B 2.00E-15 HDL 9 14971602:15371661 1.30E-13 rs643531 8.10E-18 rs581080 rs686030 2 98 10 89 19 81
SPTY2D1 1.00E-16 TC 11 18429356:18829415 2.50E-08 rs10832963 7.20E-17 rs10832963 rs10832963 < 1 99 3 97 6 94
11 18427988:18828047 2.50E-08 rs10832963 2.90E-19 rs10832963 rs10832963 < 1 99 3 97 6 94
FADS1 5.00E-18 LDL 11 61367291:61767350 1.20E-21 rs174583 2.90E-20 rs102275 rs102275 2 98 9 91 17 83
TC 11 61367291:61767350 2.10E-22 rs174550 2.90E-20 rs102275 rs102275 1 99 7 93 13 87
TG 11 61367291:61767350 5.40E-24 rs174546 2.90E-20 rs102275 rs102275 1 99 5 95 10 90
HDL 11 61367291:61767350 1.50E-22 rs174601 2.90E-20 rs102275 rs102275 < 1 99 4 96 8 92
ST3GAL4 2.00E-22 LDL 11 126084467:126484526 1.20E-15 rs11220462 7.20E-25 rs4307732 rs4307732 2 98 8 92 15 85
TC 11 126084467:126484526 2.10E-11 rs11220463 7.20E-25 rs4307732 rs7951028 1 99 7 93 13 87
MMAB 2.00E-44 HDL 12 109793364:110193423 6.90E-15 rs7134594 1.00E-38 rs7954144 rs7954144 2 97 12 88 21 79
NYNRIN 3.00E-46 LDL 14 24688259:25088318 4.40E-11 rs2332328 1.10E-78 rs6573778 rs6573778 < 1 99 3 97 5 95
CKMT1A 8.00E-28 TG 15 43791310:44191369 4.70E-08 rs9989313 1.20E-13 rs2260160 rs9989313 5 95 20 79 33 66
ALDH1A2 5.00E-08 TC 15 58334099:58734158 8.80E-20 rs1532085 5.00E-45 rs1532085 rs1532085 < 1 > 99 1 99 2 98
15 58045824:58445883 0.0042 rs4646590 0.0027 rs9796698 rs9796698 < 1 < 1 < 1 < 1 < 1 < 1
HDL 15 58334099:58734158 2.90E-96 rs1532085 5.00E-45 rs1532085 rs1532085 < 1 > 99 < 1 > 99 1 99
15 58045824:58445883 0.0014 rs6493966 0.0027 rs9796698 rs8040266 < 1 < 1 < 1 < 1 < 1 < 1
TG 15 58334099:58734158 2.40E-13 rs261342 5.00E-45 rs1532085 rs2043085 4 96 18 81 31 69
15 58045824:58445883 0.0046 rs2414536 0.0027 rs9796698 rs9796698 < 1 < 1 < 1 < 1 < 1 < 1
LIPC 7.00E-23 TC 15 58653103:59053162 8.80E-20 rs1532085 1.10E-25 rs2043085 rs2043085 < 1 > 99 1 99 3 97
HDL 15 58653103:59053162 2.90E-96 rs1532085 1.10E-25 rs2043085 rs1532085 < 1 > 99 2 98 3 97
TG 15 58653103:59053162 2.40E-13 rs261342 1.10E-25 rs2043085 rs2043085 2 98 10 89 19 81
VKORC1 7.00E-47 TG 16 30904631:31304682 3.30E-08 rs11649653 1.10E-80 rs749671 rs749671 3 97 13 87 22 77
NFATC3 3.00E-15 HDL 16 68060252:68460297 1.20E-27 rs3785108 3.30E-05 rs7204208 rs3785108 3 91 10 68 15 51
16 68051875:68451934 1.20E-27 rs3785108 0.0067 rs3743739 rs3785108 < 1 5 < 1 < 1 < 1 < 1
16 68025772:68425831 1.20E-27 rs3785108 0.00055 rs9930867 rs3785108 2 < 1 2 < 1 2 < 1
16 68063016:68463075 1.20E-27 rs3785108 0.0068 rs1868158 rs3785108 < 1 < 1 < 1 < 1 < 1 < 1
16 68060703:68460762 1.20E-27 rs3785108 4.20E-30 rs7193701 rs7204208 > 99 < 1 > 99 < 1 > 99 < 1
PERLD1 9.00E-24 HDL NA NA NA NA NA NA NA NA NA NA NA NA NA
TBKBP1 6.00E-10 TC 17 45589357:45989416 1.80E-07 rs8072100 2.10E-21 rs9913503 rs4794053 78 17 90 4 92 2
LDL 17 45589357:45989416 1.10E-07 rs8072100 2.10E-21 rs9913503 rs6503807 47 51 79 17 87 9
LIPG 4.00E-10 TC 18 46918514:47318573 2.00E-19 rs7239867 1.20E-11 rs4939883 rs4939883 1 99 5 94 11 89
HDL 18 46918514:47318573 2.70E-49 rs7241918 1.20E-11 rs4939883 rs4939883 < 1 > 99 2 98 4 96
ANGPTL4 4.00E-08 HDL 19 8239194:8639253 3.20E-08 rs7255436 3.80E-09 rs7255436 rs7255436 < 1 > 99 2 98 5 95
APOC4 4.00E-09 TG 19 45248464:45648523 1.10E-30 rs439401 9.40E-15 19:45430280 rs439401 98 2 > 99 < 1 > 99 < 1
19 45252653:45652712 1.10E-30 rs439401 1.10E-299 rs1130742 rs1130742 > 99 < 1 > 99 < 1 > 99 < 1
LILRA3 9.00E-12 HDL 19 54602026:55002085 4.30E-16 rs386000 8.20E-17 19:54793830 rs386000 < 1 > 99 4 95 9 91
CEP250 3.00E-08 TC 20 33899702:34299761 3.80E-10 rs2277862 0.022 rs17424259 rs2104417 < 1 < 1 < 1 < 1 < 1 < 1
CPNE1 7.00E-41 TC 20 34013995:34414054 3.80E-10 rs2277862 7.30E-110 rs6060524 rs6060524 95 5 99 1 99 < 1
PLTP 3.00E-18 TG 20 44327404:44727463 4.70E-18 rs4810479 1.80E-20 rs6065906 rs4810479 < 1 > 99 3 97 5 95
HDL 20 44327404:44727463 1.90E-22 rs6065906 1.80E-20 rs6065906 rs6065906 < 1 > 99 2 98 5 95
UBE2L3 6.00E-13 HDL 22 21778264:22178323 1.10E-08 22:21932068 8.90E-13 rs4821112 rs2283790 3 96 16 84 27 72
Published results of loci correlating with both liver expression and one of the four lipid traits (Teslovich et al. Supplementary Table 8) and posterior probability of different signal (PP3) and common
signal (PP4) after applying colocalisation test. Each row lists the results for one probe, and the multiple entries for the same locus and trait represent multiple probes mapping to the same locus. the
columns Biom pval and eQTL pval report the lowest p-value found for the association with the trait listed and for the liver expression association respectively, with the corresponding SNP name
(Biom SNP and eQTL SNP); the column Best Causal reports the SNP within the region with the highest posterior probability to be the true causal variant. The probabilities have been rounded
to 1 significant figure.
18
Table S2. eQTL/LDL colocalisation
Chr Region Signal PP.H3.abf PP.H4.abf Tesl Biom pval Biom SNP eQTL pval eQTL SNP Best Causal
1 109618271:110144587 CELSR2 2 98 Y 9.70E-171 rs629301 1.50E-120 rs646776 rs629301
PSRC1 7 93 Y 9.70E-171 rs629301 1.10E-299 rs7528419 rs629301
SORT1 7 93 Y 9.70E-171 rs629301 1.10E-299 rs7528419 rs629301
PSMA5 7 93 Y 9.70E-171 rs629301 1.50E-17 rs599839 rs629301
1 150767063:151167122 ANXA9 3 97 N 6.50E-08 rs267733 6.10E-08 rs267734 rs267733
1 25626305:26026364 TMEM57 10 90 Y 1.20E-10 rs12027135 2.10E-31 rs873308 rs12027135
2 120908798:121308857 INHBB 7 77 N 3.80E-07 rs2030746 4.90E-21 rs17050272 rs17050272
8 59158506:59558565 UBXN2B 13 87 N 3.90E-09 rs1030431 3.50E-10 rs11996829 rs13263105
8 8795514:9392282 PPP1R3B 4 96 Y 7.40E-15 rs2126259 6.20E-17 rs2126259 rs2126259
ENSG00000254235 13 87 N 7.40E-15 rs2126259 4.00E-13 rs4841133 rs9987289
9 2454062:2854121 VLDLR 1 91 N 8.00E-06 rs3780181 1.40E-07 rs3780181 rs3780181
11 126084467:126484526 ST3GAL4 15 85 Y 1.20E-15 rs11220462 7.20E-25 rs4307732 rs4307732
11 18429356:18829415 SPTY2D1 6 93 N 2.90E-07 rs10128711 7.20E-17 rs10832963 rs10832963
11 61367291:61767350 FADS1 17 83 Y 1.20E-21 rs174583 2.90E-20 rs102275 rs102275
12 111508189:111908248 CUX2 2 98 N 1.50E-09 rs11065987 1.00E-17 rs4378452 rs3184504
14 24688259:25088318 NYNRIN 5 95 Y 4.40E-11 rs2332328 1.10E-78 rs6573778 rs6573778
16 71894416:72310900 HP 1 97 N 1.80E-22 rs2000999 1.30E-05 rs2000999 rs2000999
HPR 1 99 N 1.80E-22 rs2000999 4.20E-08 rs2000999 rs2000999
17 45562645:45962704 KPNB1 16 83 N 1.10E-07 rs8072100 3.10E-09 rs4794048 rs8072100
20 12947054:13347113 SPTLC3 4 86 N 4.20E-06 rs364585 2.30E-41 rs168622 rs364585
Positive (PP4 > 75%) eQTL/LDL colocalisation results between the liver eQTL dataset and the
Teslovich meta-analysis using the most stringent prior for the probability that one SNP is associated
with both traits, p12 = 10
−6. The column Signal includes genes that are part of overlapping regions
and that colocalise at PP4 > 75%; the column Region represents the genomic coordinates for the start
and stop of the signal; in the column Tesl, “Y” indicates that this signal with any of the genes included
has been reported to be an intermediate for any of the four lipid biomarker associations by Teslovich et
al. ; the columns Biom pval and eQTL pval report the lowest p-value found for LDL association and
for the expression association respectively, with the corresponding SNP name (Biom SNP and eQTL
SNP); the column Best Causal reports the SNP within the region with the highest posterior
probability to be the true causal variant. The probabilities have been rounded to 1 significant figure.
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Table S3. eQTL/HDL colocalisation
Chr Region Signal PP.H3.abf PP.H4.abf Tesl Biom pval Biom SNP eQTL pval eQTL SNP Best Causal
1 109618271:110144587 CELSR2 3 97 N 6.20E-08 rs629301 1.50E-120 rs646776 rs646776
PSRC1 7 93 N 6.20E-08 rs629301 1.10E-299 rs7528419 rs629301
SORT1 7 93 N 6.20E-08 rs629301 1.10E-299 rs7528419 rs629301
PSMA5 7 92 N 6.20E-08 rs629301 1.50E-17 rs599839 rs12740374
2 85349026:85749085 TGOLN2 17 83 N 1.00E-07 rs1053560 2.80E-80 rs1044973 rs1044973
4 102982958:103383017 SLC39A8 1 99 Y 7.20E-11 rs13107325 3.80E-21 rs13107325 rs13107325
8 8795514:9392282 PPP1R3B 14 86 Y 6.40E-25 rs9987289 1.90E-17 rs4240624 rs9987289
ENSG00000254235 4 96 N 6.40E-25 rs9987289 4.00E-13 rs4841133 rs9987289
9 14971602:15371661 TTC39B 19 81 Y 1.30E-13 rs643531 8.10E-18 rs581080 rs686030
11 61367291:61767350 FADS1 8 92 Y 1.50E-22 rs174601 2.90E-20 rs102275 rs102275
12 109793364:110193423 MMAB 21 79 Y 6.90E-15 rs7134594 1.00E-38 rs7954144 rs7954144
12 111508189:111908248 CUX2 2 89 N 4.40E-06 rs4766578 2.80E-16 rs3184504 rs3184504
15 58334099:59053162 ALDH1A2 1 99 Y 2.90E-96 rs1532085 5.00E-45 rs1532085 rs1532085
LIPC 3 97 Y 2.90E-96 rs1532085 1.10E-25 rs2043085 rs1532085
15 96517293:96917352 ENSG00000259359 2 87 N 8.00E-06 rs8023580 5.50E-13 rs8023580 rs8023580
18 46918514:47318573 LIPG 4 96 Y 2.70E-49 rs7241918 1.20E-11 rs4939883 rs4939883
19 54578320:55002085 LILRB2 9 88 N 4.30E-16 rs386000 1.70E-06 rs416867 rs386000
LILRA3 9 91 Y 4.30E-16 rs386000 8.20E-17 19:54793830 rs386000
19 8239194:8639253 ANGPTL4 5 95 Y 3.20E-08 rs7255436 3.80E-09 rs7255436 rs7255436
20 44327404:44727463 PLTP 5 95 Y 1.90E-22 rs6065906 1.80E-20 rs6065906 rs6065906
Positive (PP4 > 75%) eQTL/HDL colocalisation results between the liver eQTL dataset and the
Teslovich meta-analysis. Column and row headings are the same as in previous figure.
20
Table S4. eQTL/TG colocalisation
Chr Region Signal PP.H3.abf PP.H4.abf Tesl Biom pval Biom SNP eQTL pval eQTL SNP Best Causal
2 2754647:28005583 GCKR 5 77 N 5.70E-133 rs1260326 1.50E-05 rs1260326 rs1260326
C2orf16 4 81 N 5.70E-133 rs1260326 8.30E-06 rs1260326 rs1260326
10 94637063:95037122 CYP26A1 3 95 N 2.40E-08 rs2068888 3.50E-06 rs4418728 rs2068888
11 61367291:61767350 FADS1 10 90 Y 5.40E-24 rs174546 2.90E-20 rs102275 rs102275
15 58653103:59053162 LIPC 19 81 Y 2.40E-13 rs261342 1.10E-25 rs2043085 rs2043085
16 30904631:31304682 VKORC1 23 77 Y 3.30E-08 rs11649653 1.10E-80 rs749671 rs749671
ENSG00000255439 23 77 N 3.30E-08 rs11649653 1.10E-80 rs749671 rs749671
16 71894416:72310900 HP 2 75 N 5.70E-06 rs2000999 2.10E-06 rs2000999 rs2000999
HPR 2 89 N 5.70E-06 rs2000999 4.20E-08 rs2000999 rs2000999
20 44327404:44727463 PLTP 5 95 Y 4.70E-18 rs4810479 1.80E-20 rs6065906 rs4810479
Positive (PP4 > 75%) eQTL/TG colocalisation results between the liver eQTL dataset and the
Teslovich meta-analysis. Column and row headings are the same as in previous figure.
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Table S5. eQTL/TC colocalisation
Chr Region Signal PP.H3.abf PP.H4.abf Tesl Biom pval Biom SNP eQTL pval eQTL SNP Best Causal
1 109618271:110144587 CELSR2 3 97 Y 5.80E-131 rs629301 1.50E-120 rs646776 rs629301
PSRC1 7 93 Y 5.80E-131 rs629301 1.10E-299 rs7528419 rs629301
SORT1 7 93 Y 5.80E-131 rs629301 1.10E-299 rs7528419 rs629301
PSMA5 7 93 Y 5.80E-131 rs629301 1.50E-17 rs599839 rs629301
1 25626305:26026364 TMEM57 11 89 Y 4.10E-11 rs12027135 2.10E-31 rs873308 rs12027135
2 20201795:20601854 SDC1 17 82 N 1.20E-07 rs1473886 6.70E-09 rs907866 rs1107851
2 27546474:28005583 GCKR 5 77 N 7.30E-27 rs1260326 1.50E-05 rs1260326 rs1260326
C2orf16 4 81 N 7.30E-27 rs1260326 8.30E-06 rs1260326 rs1260326
3 32322873:32722932 CMTM6 8 77 N 9.10E-07 rs7640978 2.70E-07 rs17029597 rs17029597
6 34355095:34755154 C6orf106 15 85 N 4.70E-11 rs2814982 4.50E-09 rs3800461 rs3800461
8 59158506:59558565 UBXN2B 15 85 N 8.80E-13 rs1030431 3.50E-10 rs11996829 rs13263105
8 8795514:9195573 PPP1R3B 3 97 Y 9.00E-24 rs2126259 6.20E-17 rs2126259 rs2126259
9 14971602:15371661 TTC39B 1 99 N 3.10E-09 rs581080 8.10E-18 rs581080 rs581080
10 17079389:17479448 VIM 5 93 N 7.20E-07 rs7903259 9.80E-09 rs10904908 rs7903259
11 126084467:126484526 ST3GAL4 13 87 Y 2.10E-11 rs11220463 7.20E-25 rs4307732 rs7951028
11 18429356:18829415 SPTY2D1 6 94 Y 2.50E-08 rs10832963 7.20E-17 rs10832963 rs10832963
11 61367291:61767350 FADS1 13 87 Y 2.10E-22 rs174550 2.90E-20 rs102275 rs102275
12 111508189:111908248 CUX2 2 98 N 2.40E-11 rs4766578 2.80E-16 rs3184504 rs3184504
14 24688259:25088318 NYNRIN 3 97 N 1.10E-07 rs6573778 1.10E-78 rs6573778 rs6573778
15 58334099:59053162 ALDH1A2 2 98 Y 8.80E-20 rs1532085 5.00E-45 rs1532085 rs1532085
LIPC 3 97 Y 8.80E-20 rs1532085 1.10E-25 rs2043085 rs2043085
16 56310220:56710279 OGFOD1 7 84 3.20E-06 rs11644679 3.40E-11 rs11649379 rs11644679
16 71894416:72310900 HP 1 97 N 3.20E-24 rs2000999 2.10E-06 rs2000999 rs2000999
HPR 1 99 N 3.20E-24 rs2000999 4.20E-08 rs2000999 rs2000999
17 45562645:45962704 KPNB1 13 86 N 1.80E-07 rs8072100 3.10E-09 rs4794048 rs8072100
18 46918514:47318573 LIPG 11 89 Y 2.00E-19 rs7239867 1.20E-11 rs4939883 rs4939883
22 46433083:46833138 PPARA 10 81 N 3.60E-06 rs4253772 6.00E-08 rs11704979 rs4253772
Positive (PP4 > 75%) eQTL/TC colocalisation results between the liver eQTL dataset and the
Teslovich meta-analysis. TColumn and row headings are the same as in previous figure.
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Figure S6. Regional Manhattan plots corresponding to loci listed in Table 2 of main
text. Row and column headers defined as in previous figure. The genomic range may be greater
than ∼ 400 kilobases to improve visualisation of the signal.
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Overview of gene function of new colocalisation results associated with blood
lipid levels and liver expression
• SDC1 (Syndecan-1) encodes a transmembrane heparan sulfate proteoglycan which mediates the
clearance of triglyceride-rich lipoproteins in liver [16].
• TGOLN2 (Trans-Golgi Network Protein 2) encoded by this gene regulates cholesterol transport to
the trans-Golgi network and plasma membrane caveolae [17].
• INHBB encodes Inhibin beta B, a subunit of both activin and inhibin. This locus has been reported
associated with elevated levels of lipids and cardiovascular disease risk traits [18].
• UBXN2B (UBX Domain Protein 2B) encodes a protein containing a UBX-domain involved in
endoplasmic reticulum-associated degradation, a process which is crucial for lipid droplets mainte-
nance [19].
• VLDLR (Very Low Density Lipoprotein Receptor) is known to play important roles in VLDL-
triglyceride metabolism, and has been previously correlated with glucose and triglyceride plasma
levels [20].
• VIM codes for Vimentin, and a functional role for vimentin intermediate filaments has been reported
in the metabolism of lipoprotein-derived cholesterol [21].
• CYP26A1 encodes an endoplasmic reticulum protein which regulates the the cellular level of retinoic
acid, a critical signalling molecule involved in the regulation of gene expression. This protein
belongs to the cytochrome P450 superfamily of enzymes which catalyse many reactions involved in
maintenance of lipid homeostasis and drug metabolism [22].
• OGFOD1 (2-oxoglutarate and iron-dependent oxygenase domain containing 1) is crucial for cellular
adaptation to changes in oxygen concentration, and has been reported to function in ischaemic
signalling [23].
• HP encodes the plasma protein haptoglobin, which binds and transports free hemoglobin (Hb)
released from erythrocytes back to the liver for recycling, thereby inhibiting haemoglobin’s oxidative
activity [24].
• Haptoglobin-related protein (HPR) is a plasma protein associated with apolipoprotein-L-I contain-
ing high-density lipoprotein (HDL) particles, and has been shown to be part of the innate immune
response [25].
HP and HPR have been previously associated with lipids [26].
• PPARA gene encodes the transcription factor peroxisome proliferator-activated receptor alpha
(PPAR-alpha), a major regulator of lipid metabolism in the liver. PPAR-alpha serves as cellu-
lar receptor for fibrates, an anti-dyslipidemia drug that effectively lower serum triglycerides and
raise serum HDL-cholesterol levels [27].
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